#Japan #Tokyo #regenerative medicine #ReeNT #Tokyo Jikei University

Strategic Capital Partnership to Advance Regenerative Medicine in ENT

In a significant move within the medical community, a strategic partnership has been formed between a pioneering venture company, ReeNT, established by Tokyo Jikei University, and Alfresa Holdings Corporation. This collaboration aims to delve deeper into the practical application of regenerative medicine products specifically targeting challenging conditions in the realm of otolaryngology, which covers disorders of the ear, nose, and throat. On May 27, 2026, the two entities entered a capital and business alliance to explore opportunities related to manufacturing and distribution in regenerative medicine.

Background of the Collaboration

One of the critical focal points of this partnership is the management of cholesteatoma, a persistent and often challenging disease affecting the middle ear. This condition leads to the formation of an abnormal tissue known as cholesteatoma, which slowly destructive properties can damage surrounding tissues and bone, potentially leading to severe complications like hearing loss, discharge from the ear, meningitis, and brain abscess if left untreated. Current treatment options remain limited primarily to surgical interventions, where removal of the cholesteatoma can unfortunately result in the loss of middle ear mucosa, raising concerns over recurrence and further hearing degradation.

Tokyo Jikei University's Department of Otolaryngology has dedicated over 20 years to researching the regeneration of middle ear mucosa post-surgery. To bring this valuable research to fruition in a societal context, ReeNT was formed. The venture focuses on developing regenerative medical products targeted at middle ear diseases. Among these innovations is a product consisting of an epithelial cell sheet derived from the patient's own nasal mucosa, which aims to promote the regeneration of middle ear mucosa, helping to prevent the obstruction of the middle ear space and enhance air circulation.

With a strong commitment to ensuring stable supply chains for pharmaceutical products and healthcare, the Alfresa Group emphasizes its support in the regenerative medicine arena. This encompasses the entire chain from raw material provision to distribution to healthcare facilities, termed the Total Supply Chain Service (TSCS). The group's subsidiary, Cell Resources Co., Ltd., is enhancing service capabilities to facilitate the domestic production of cellular raw materials and establish an extensive Contract Development and Manufacturing Organization (CDMO) service framework.

The organized alliance between Alfresa and ReeNT looks to leverage both companies’ strengths in expediting the practical introduction of these advanced regenerative medical technologies. The Alfresa Group plans to focus on supporting the domestic application of ReeNT's epithelial cell sheets, utilizing various capabilities throughout the regenerative medicine TSCS, including Clinical Research Organization (CRO) functionalities, manufacturing, and distribution.

Details of the Capital and Business Alliance

Capital Partnership Details

• - Number of Shares Acquired: 1,000 common shares of ReeNT
• - Total Payment Amount: 600 million yen
• - Equity Stake Post-Investment: 16.1% of total shares outstanding
• - Use of Funds: This investment is designated for the research, development, manufacturing, regulatory approval, and commercialization of the epithelial cell sheet and its successors, along with related operational activities.

Business Collaboration Details

Both companies will work collaboratively towards the development and commercialization of these products within Japan. Alfresa will assist ReeNT in conducting clinical development and leveraging CRO and manufacturing capabilities as part of a comprehensive support structure along the entire product lifecycle.

ReeNT Company Overview (As of May 27, 2026)

ReeNT is recognized as a university-originated company focusing on innovative solutions in the medical field. Their commitment to developing regenerative treatments is paving the way for improved patient outcomes in ear-related diseases.

Future Outlook

While the immediate financial impact of this partnership is not expected to be significant, the long-term benefits could substantially contribute to enhancing the corporate value of Alfresa Group. As developments progress, further disclosures will be made promptly as necessary.

This strategic partnership not only showcases a promising advancement in healthcare but also embodies a significant commitment to addressing the challenges posed by difficult-to-treat diseases in otolaryngology. The joint efforts of Alfresa and ReeNT are anticipated to yield groundbreaking solutions in regenerative medicine, benefiting patients and healthcare providers alike.